Perspective Therapeutics, Inc. (CATX)
NYSEAMERICAN: CATX · Real-Time Price · USD
0.9431
+0.1007 (11.95%)
Nov 13, 2026, 4:00 PM EST - Market closed
Perspective Therapeutics Employees
As of December 31, 2025, Perspective Therapeutics had 166 total employees, including 163 full-time and 3 part-time employees. The number of employees increased by 26 or 18.57% compared to the previous year. That makes Perspective Therapeutics the 28,149th largest employer in the world and 3,551st in the United States.
Employees
166
Change (1Y)
26
Growth (1Y)
18.57%
Revenue / Employee
$1,325
Profits / Employee
-$740,404
Market Cap
113.89M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 166 | 26 | 18.57% | 163 | 3 |
| Dec 31, 2024 | 140 | 21 | 17.65% | 138 | 2 |
| Dec 31, 2023 | 119 | 28 | 30.77% | 116 | 3 |
| Sep 30, 2023 | 91 | - | - | 91 | 0 |
| Jun 30, 2023 | 91 | - | - | 91 | 0 |
| Mar 31, 2023 | 91 | - | - | 91 | 0 |
| Jun 30, 2021 | 61 | 8 | 15.09% | 61 | 0 |
| Jun 30, 2020 | 53 | 10 | 23.26% | 53 | 0 |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Neuronetics | 658 |
| Outset Medical | 310 |
| Pulmonx | 296 |
| Apyx Medical | 205 |
| Nyxoah | 154 |
| Owlet | 114 |
| TriSalus Life Sciences | 102 |
| Hyperfine | 102 |
CATX News
- 1 day ago - Perspective Therapeutics price target lowered to $1 from $5 at BofA - TheFly
- 4 days ago - Perspective Therapeutics reports Q3 EPS (27c), consensus (25c) - TheFly
- 4 days ago - Perspective Therapeutics price target lowered to $8 from $14 at Piper Sandler - TheFly
- 4 days ago - Perspective Therapeutics price target lowered to $8 from $11 at Truist - TheFly
- 5 days ago - Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2026 Results - GlobeNewsWire
- 5 days ago - Perspective Therapeutics Earnings release: Q3 2026 - Filings
- 5 days ago - Perspective Therapeutics Quarterly report: Q3 2026 - Filings
- 8 days ago - Perspective Therapeutics presents VMT01 monotherapy data from Phase 1/2a study - TheFly